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Abstract: In this paper, a retuning strategy for a controller is proposed in order to improve
the reference BIS tracking in patients, by means of simultaneous administration of propofol and
of remifentanil, in the presence of model uncertainties. This strategy proves to be useful as is
shown by simulations.
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1. INTRODUCTION
One of the most important concerns of the anesthetists
during surgery is the administration of the right combi-
nation of drugs in order to achieve a desired depth of
anesthesia (DoA). The DoA consists of two components,
the hypnosis and the analgesia. The study presented in this
paper concerns the case where hypnosis and analgesia are
achieved, respectively, by the administration of propofol
and of remifentanil. Moreover, following several studies
(Tire´n et al. [2005], Grindsta  and Tobias [2004], Ekman
et al. [2004], Wodey et al. [2005], Whyte and Booker
[2003]) and clinical practice, the level of DoA is measured
by means of the bispectral index (BIS). This index is a
single dimensionless number, which is computed from the
electroencephalogram (EEG) and ranges from 0 (equiva-
lent to EEG silence) to 100 (equivalent to fully awake and
alert). According to medical practice a BIS value between
40 and 60 corresponds to an appropriate DoA level for
general anesthesia.
After an adequate model for the BIS response of a pa-
tient to the administration of propofol and remifentanil is
identified, the desired BIS value may be tracked by the au-
tomatic controller developed in Nogueira et al. [2014] (see
also Nogueira et al. [2012]). However, in the presence of
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uncertainties, due to errors in modeling and identification
procedures, the BIS obtained may be di erent from the
desired one. In this work, we present a controller retuning
strategy in order to overcome this problem. The proposed
retuning strategy improves the BIS reference tracking as
illustrated by simulations.
2. MODEL DESCRIPTION
The patient BIS response to the administration of propofol
and of remifentanil is commonly modeled as a high or-
der pharmacokinetic/pharmacodynamic (PK/PD) Wiener
model, which is constituted by a dynamic linear part
based on the relevant patient characteristics (see Bailey
and Haddad [2005], Schnider et al. [1998], Marsh et al.
[1991], Minto et al. [1997]) and by a nonlinear static part
(see Minto et al. [2000]). However, a new Wiener model
(parameter parsimonious Wiener model) with a reduced
number of parameters describing the joint e ect of propofol
and of remifentanil has been introduced in Silva et al.
[2010].
In the parameter parsimonious model (PPM) the relation
between the propofol and remifentanil dosages and the cor-
responding e ect concentrations (cpe and cre) are modeled
by the transfer functions:
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Hp(s) = k1k2k3–
3
(k1–+ s)(k2–+ s)(k3–+ s)
up(s), (1)
Hr(s) = l1l2l3÷
3
(l1÷ + s)(l2÷ + s)(l3÷ + s)
ur(s), (2)
respectively, where – and ÷ are patient dependent parame-
ters, without any physiological meaning. The correspond-
ing BIS level, z(t), usually given by the generalized Hill
equation Minto et al. [2000], is approximated in Silva et al.
[2010] by the nonlinear equation:
z(t) = z01 + (U(t))“ , (3)
where U(t) = µUp+Ur, and µ and “ are patient dependent
parameters, without any physiological meaning, z0 is the
BIS level at zero concentration, and Up and Ur respec-
tively denote the potencies of propofol and remifentanil,
which are obtained by normalizing the e ect concentra-
tions with respect to the concentrations that produce half
the maximal e ect when the drug acts isolated (denoted
by ECp50 and ECr50, respectively), i.e.:
Up = c
p
e
ECp50
and Ur = c
r
e
ECr50
. (4)
The parameters ECp50 and ECr50 are taken to be fixed,
namely ECp50 = 10 mg/ml and ECr50 = 0.01 mg/ml.
These values were obtained in the work developed in
Mendonc¸a et al. [2012], to which we refer for further
explanation.
3. DEPTH OF ANESTHESIA CONTROLLER
In the work developed in Nogueira et al. [2014] (see also
Nogueira et al. [2012]), a nonlinear controller was pre-
sented in order to track a desired reference value for the
BIS level, by means of simultaneous administration of
propofol and of remifentanil. This controller results from
a combination of a linear control law with a positivity
constraint for the drug doses and is based on the state
space realizations  p = (Ap, Bp, Cp) of the transfer func-
tion Hp(s) and  r = (Ar, Br, Cr) of Hr(s). The matrices
of such realizations are as follows:
Ap =
C≠10– 0 0
9– ≠9– 0
0 – ≠–
D
,
Bp =
C 10–
0
0
D
,
Cp = [ 0 0 1 ] ,
Ar =
C≠3÷ 0 0
2÷ ≠2÷ 0
0 ÷ ≠÷
D
,
Br =
C 3÷
0
0
D
,
Cr = [ 0 0 1 ] .
(5)
Further, the states of  p and of  r are respectively denoted
by xp and xr.
The controller is then defined by:
u(t) =
5
up(t)
ur(t)
6
=
5
max(0, u˜p(t)
max(0, u˜r(t)
6
, (6)
where up is the input of propofol and ur is the input of
remifentanil, with:5
u˜p
u˜r
6
= E (≠KAx+ ⁄(Mú ≠Kx)) , (7)
where
x =
5
xp
xr
6
, (8)
A =
5
Ap 0
0 Ar
6
, (9)
E =
5
fl
1
6 1
–fl+ 300÷ , (10)
Mú = 3(0.1fl+ 100)0.1µfl+ 100
1 z0
zú
≠ 1
2 1
“
, (11)
K = [ 0.1 0.1 0.1 100 100 100 ] , (12)
zú is the desired BIS level, and ⁄ and fl are positive
design parameters that do not a ect the tracked reference
value and can be chosen according to clinical criteria.
The parameter ⁄ influences the convergence speed to the
desired reference value and the parameter fl can be inter-
preted as the proportion between the doses of propofol and
remifentanil.
For more details about this controller and its tracking
properties, the reader is referred to Nogueira et al. [2014]
or to Nogueira et al. [2012].
4. RETUNING STRATEGY FOR DOA CONTROL
In this section a strategy is presented to retune the
controller described in Section 3 in order to overcome
the problems raised by uncertainty in the BIS patient
modeling process. The idea is to change the reference value
for the parameter Mú in the control law (7) according to
the response of the patient when the controller is applied.
For this purpose, we assume that the uncertainties in the
model only occur in its linear part and in the parameter µ,
the parameter “ of the Hill equation (3) is considered to
be known. A simple procedure to identify the parameter
“ can be found in the work developed in Nogueira et al.
[2013].
In the sequel, we denote by Mrefmodel the target value used
in the control law applied to the PPM used to describe
a patient in order to achieve a certain reference value for
the BIS, Umodel(t) denoted the theoretical potency U(t)
obtained for the PPM and Upatient(t) denotes the potency
U(t) obtained for a real patient.
It follows from what has been presented in Nogueira et al.
[2014], and summarized in the previous section, that when,
in the controller (7), the parameter Mú is set to:
Mú =Mrefmodel =
3(0.1fl+ 100)
0.1µfl+ 100
1 z0
zú
≠ 1
2 1
“
, (13)
the desired BIS value zú is achieved to the corresponding
PPM. This means that the potency Umodel(t) converges to
a value
Uú = “
Ú
z0
zú
≠ 1 (14)
= ·Mrefmodel, (15)
with · = 0.1µfl+1003(0.1fl+100) .
However, when the controller is tuned with the parameter
Mú = Mrefmodel as in (13), the BIS level obtained in a real
patient will be equal to a certain value z¯ instead of the
desired one, zú. This means that Upatient(t) converges to
a value
U¯ = “
Ú
z0
z¯ ≠ 1 . (16)
The retuning strategy presented here is based on the
assumption that the patient is correctly modeled by a
PPM. Moreover it is assumed that the misfit in the
achieved BIS values is due to the fact that the actual
patient PPM di ers from the initially considered one. In
this case, the same type of relationship exists as for the
original PPM between the steady state value of U(t) and
the value of Mú taken in the control law (7). I.e., setting
Mú = M¯ and applying the corresponding control law to
the patient yields a steady state value of U(t)
U¯ = ·¯M¯, (17)
for an adequate value of ·¯ . Since M¯ is known, the value of
·¯ can be computed by letting the system settle down and
computing U¯ . In particular, if ones observers that setting
Mú = Mrefmod yields a state Uúú (”= Uú) for U(t) one can
conclude that
·¯ = U
úú
Mrefmod
. (18)
This means that, in order to track the BIS reference value
zú, or equivalently in order to achieve the steady state
value Uú for U(t), the adequate value forMú in (7) should
be given by:
Mú = U
ú
·¯
… (19)
Mú = U
ú
UúúM
ref
mod. (20)
Therefore an improvement of the reference tracking perfor-
mance can be obtained by means of the following strategy:
Given a PPM for a patient:
(1) Compute the value Mú =Mrefmod as in (11) according
to the PPM parameters.
(2) Compute the theoretical steady state value Uú of U(t)
according to equation (14).
(3) Apply the corresponding control law (7) to deliver the
adequate doses of propofol and remifentanil.
(4) Observe the patient response, read out the BIS steady
state value zúú and compute the corresponding steady
state value Uúú of the combined potency U(t).
(5) Retune the value of Mú in (7) according to the
equation (20).
5. SIMULATIONS
In this section, the performance of the retuning strategy
for the improvement of the performance of the controller
(7) is illustrated by simulations. For this purpose, the
control law is applied to a simulated patient that was set
up based on the data of a real patient, a woman, with
68 years of age, a height of 158 cm, and 113 Kg who was
subject to general anesthesia under propofol and remifen-
tanil administration during a breast surgery. The DoA
was monitored by the BIS and was manually controlled
around clinically accepted values by the anesthetist. Alaris
GH pumps were used for both propofol and remifentanil.
Infusion rates, BIS values and other physiological variables
were acquired every five seconds (Mendonc¸a et al. [2012]).
For this patient, a PK/PD Wiener model (other than
the PPM) was obtained as follows. The linear part was
modeled according to Marsh et al. [1991], Minto et al.
[1997], and Schnider et al. [1998] based on the relevant
patient characteristics. The corresponding model is sum-
marized in equation (1) of Ionescu et al. [2011], which was
used here with age = 68, height = 158 cm and weight
= 113 Kg. The nonlinear part was taken to coincide with
the generalized Hill equation (3) and the corresponding
parameters “ and µ were identified in Mendonc¸a et al.
[2012] from the surgery data, being given by: “ = 1.09 and
µ = 2.40.
In order to test the proposed control retuning strategy,
the controller is first tuned assuming that the simulated
patient is modeled by the parsimonious parameter Wiener
model of Silva et al. [2010], with parameters –, ÷, and “
identified as in Mendonc¸a et al. [2012]. These parameters
were made available to us by the authors in a private
communication and are given by – = 0.0687, ÷ = 4.5413,
and “ = 1.09. In order to increase the misfit between the
theoretical model, PPM, and the simulated patient model,
instead of the value µ = 2.40, identified for the patient,
another value for µ is chosen in the PPM, namely µ = 1.79.
This value is the average of the values for µ taken from a
bank of identified values for eighteen real patients obtained
in the work developed in Mendonc¸a et al. [2012]
Figure 1 shows the BIS response of the patient using the
controller (7) without applying the retuning strategy. In
this case, the BIS response of the patient converged to 67
instead for the desired reference value, zú = 50, i.e., the
BIS is a ected by an error of 34%.
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Fig. 1. BIS evolution of a simulated patient without
applying the retuning strategy. The desired BIS level
is set to be 50.
The illustration of the BIS response of the patient with the
retuning strategy is presented in Figures 2 and 3. In Fig. 2
the new reference Mú was computed at time t1 = 20 min
(when steady state was almost achieved), improving the
BIS response of this patient, which converged to 48, value
quite close to the desired one. The error of 4%, occurred in
this case, would be smaller if the retunig happened latter
in steady state. However, another retuning may be made,
as shown in Fig. 3, where a second retuning occurred at the
instant t2 = 60 min (when the steady state was achieved),
which led the BIS response to converge to the desired value
zú = 50.
0 20 40 60 80 100 120
0
10
20
30
40
50
60
70
80
90
100
B
IS
Time[min]
 
 
BIS evolution of a simulated patient
Fig. 2. BIS evolution of a patient modeled by a PK/PD
model with a retune strategy applied at time t =
20 min. The desired BIS level is set to be 50.
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Fig. 3. BIS evolution of a patient modeled by a PK/PD
model with a retune strategy applied at time instants
t1 = 20 min and t2 = 60 min. The desired BIS level
is set to be 50.
6. EPILOGUE
In this paper, a controller retuning strategy was proposed
in order to improve the BIS reference tracking in patients,
by means of simultaneous administration of propofol and
of remifentanil, in the presence of model uncertainties.
For this purpose, the patient is simulated by the PK/PD
Wiener model proposed in Marsh et al. [1991], Minto et al.
[1997], and Schnider et al. [1998], while the controller is
tuned for a PPM. Assuming that the misfit in the patient
response is due to the existence of errors in the parameters
of the PPM, a controller retuning strategy is obtained that
improves the reference tracking, as has been shown in the
presented simulations.
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